효소보충요법 시장 규모, 점유율, 동향 분석 보고서 : 제품별, 치료 질환별, 투여 경로별, 최종 용도별, 지역별, 부문별 예측(2025-2030년)

Enzyme Replacement Therapy Market Size, Share & Trends Analysis Report By Product (Imiglucerase), By Therapeutic Condition (MPS), By Route Of Administration (Oral), By End-use, By Region, And Segment Forecasts, 2025 - 2030

US $ 5,950 ￦ 8,152,000

Unprintable PDF & Excel (Single User License)

보고서 PDF 및 엑셀을 1인만 사용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 불가능합니다.

US $ 6,950 ￦ 9,522,000

Printable PDF & Excel (5-User License)

보고서 PDF 및 엑셀을 동일 기업 내 동일 부서에서 최대 5명까지 사용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 가능합니다.

US $ 8,950 ￦ 12,262,000

Printable PDF & Excel (Enterprise License)

보고서 구매 기업 및 그 자회사, 관계사가 사용할 수 있는 라이선스이며, PDF 및 엑셀 텍스트 등의 복사 및 붙여넣기, 인쇄가 가능합니다.

한글목차

효소보충요법 시장 성장과 동향

Grand View Research, Inc.의 최신 보고서에 따르면, 세계 효소보충요법 시장 규모는 2030년까지 172억 6,000만 달러에 달할 것으로 예상되며, 2025-2030년까지 연평균 9.0%의 성장률을 보일 것으로 예상됩니다. Diseases Information Center(GARD)에 따르면, 희귀질환은 20만 명 이하에게만 발병하는 질환으로 정의됩니다. 이들 질환은 이전에는 제약사의 지원이 없었기 때문에 희귀질환이라고도 불립니다. 1983년 미국에서 희귀질환 치료제 법이 제정된 이후, 몇몇 대형 제약사 및 바이오 제약사들은 희귀질환 치료제 개발에 많은 투자를 해왔습니다. 이러한 인식 개선, R&D 투자 증가, 라이소좀 저장증 및 유전성 질환의 증가, 쉬운 의약품 승인 절차 등이 예측 기간 동안 시장 성장을 촉진하는 요인으로 작용할 것으로 보입니다.

미국 국립보건원 자료에 따르면, 희귀질환을 앓고 있는 미국인은 2,500만 명이 넘는 것으로 추산됩니다. 이러한 사실은 이들 질환의 수는 적지만, 환자 수는 많다는 사실을 보여줍니다. 효소보충요법을 사용하는 가장 흔한 라이소좀 저장 장애에는 고셔, 파브리, 퐁페, MPS, SCID, 슈왁만-다이아몬드 증후군 등이 있습니다.

최근 몇 년 동안 희귀질환은 큰 주목을 받으며 성장에 긍정적인 영향을 미치고 있습니다. 제약회사들이 희귀질환 치료제 개발에 투자할 수 있도록 다양한 보조금과 법률이 마련돼 있습니다. 희귀의약품 심사 지정 프로그램, 희귀 소아질환 우선 심사 바우처 프로그램, 인도적 사용 기기(HUD) 프로그램, 희귀제품 임상 검사 보조금 프로그램 등이 희귀의약품 개발을 지원하는 프로그램입니다.

재택 의료 및 수액 센터에서 효소 대체 요법의 사용이 증가하면서 시장을 주도하고 있습니다. 이러한 전문 수액 센터는 예측 기간 동안 가장 높은 CAGR을 기록할 것으로 예상됩니다. 병원은 접근성이 용이하고 다양한 질병을 치료할 수 있기 때문에 가장 큰 부문 점유율을 차지하고 있습니다.

효소보충요법 시장 보고서 하이라이트

• 고셔병은 2024년 32.6%의 가장 큰 매출 점유율을 차지하며 시장에서 지배적인 위치를 차지하고 있습니다.
• 이미글루세라제는 2024년 20.2%의 최대 매출 점유율을 차지하며 시장을 장악했습니다. 이는 고셔병의 유병률이 증가하고 효과적인 치료 옵션이 필요하기 때문입니다. 또한, 인식과 진단율이 향상됨에 따라 더 많은 환자가 확인되어 이미글루세라제에 대한 수요가 증가하고 있습니다.
• 비경구용은 2024년 80.9%의 가장 큰 매출 점유율을 차지하며 시장을 장악했습니다. 이러한 성장은 빠른 흡수와 효과적인 약물전달을 촉진하는 능력에 기인합니다. 또한, 이 방법은 효소와 같은 큰 분자를 혈류에 직접 주입하여 즉각적인 치료 효과를 보장하는 데 필수적인 점적투여가 가능합니다.
• 수액 주입 센터는 2024년 40.8%의 가장 큰 매출 점유율을 차지하며 시장을 주도했습니다. 이 센터는 ERT를 투여할 수 있는 통제된 환경을 제공하여 수액 주입 중 환자의 안전과 편안함을 보장합니다.

목차

제1장 조사 방법과 범위

제2장 주요 요약

제3장 효소보충요법 시장 변수, 동향, 범위

• 시장 계통 전망
• 시장 역학
  • 시장 성장 촉진요인 분석
  • 시장 성장 억제요인 분석
• 비즈니스 환경 분석
  • 산업 분석 - Porter's Five Forces 분석
  • PESTLE 분석

제4장 효소보충요법 시장 : 제품 비즈니스 분석

• 제품 시장 점유율, 2024년과 2030년
• 제품 부문 대시보드
• 시장 규모와 예측과 동향 분석, 제품별, 2018-2030년
• Imiglucerase
• Agalsidase Beta
• Alglucosidase Alfa
• Taliglucerase
• Velaglucerase Alfa
• Pegademase
• Laronidase
• Pancreatic Enzymes
• Idursulfase
• Galsulfase
• 기타

제5장 효소보충요법 시장 : 치료 질환 비즈니스 분석

• 치료 질환 시장 점유율, 2024년과 2030년
• 치료 질환 부문 대시보드
• 시장 규모와 예측과 동향 분석, 치료 질환별, 2018-2030년
• 고셰병
• MPS
• SCID
• 폼페병
• 파브리병
• 기타

제6장 효소보충요법 시장 : 투여 경로 비즈니스 분석

• 투여 경로 시장 점유율, 2024년과 2030년
• 투여 경로 부문 대시보드
• 시장 규모와 예측과 동향 분석, 투여 경로별, 2018-2030년
• 비경구
• 경구

제7장 효소보충요법 시장 : 최종 용도 비즈니스 분석

• 최종 용도 시장 점유율, 2024년과 2030년
• 최종 용도 부문 대시보드
• 시장 규모와 예측과 동향 분석, 최종 용도별, 2018-2030년
• 점적 센터
• 병원
• 기타

제8장 효소보충요법 시장 : 제품, 치료 질환, 최종 용도, 지역별, 추정·동향 분석

• 지역별 시장 점유율 분석, 2024년과 2030년
• 지역별 시장 대시보드
• 시장 규모, 예측 동향 분석, 2018-2030년
• 북미
  • 미국
  • 캐나다
  • 멕시코
• 유럽
  • 영국
  • 독일
  • 프랑스
  • 이탈리아
  • 스페인
  • 노르웨이
  • 덴마크
  • 스웨덴
• 아시아태평양
  • 일본
  • 중국
  • 인도
  • 한국
  • 호주
  • 태국
• 라틴아메리카
  • 브라질
  • 아르헨티나
• 중동 및 아프리카
  • 남아프리카공화국
  • 사우디아라비아
  • 아랍에미리트
  • 쿠웨이트

제9장 경쟁 구도

• 참여자 개요
• 기업의 시장 포지션 분석
• 기업 분류
• 전략 매핑
• 기업 개요/상장 기업
  • Carl Zeiss Meditec, Inc.
  • Shire Plc,
  • Sanofi SA
  • Biomarin Pharmaceutical Inc.
  • AbbVie
  • Alexion Pharmaceuticals Inc.
  • Allergan plc
  • Horizon Pharma Public Limited Company
  • Actelion(Janssen)
  • Recordati Rare Diseases
  • Protalix BIoTherapeutics
  • Amicus Therapeutics, Inc.

ksm

영문 목차

영문목차

Enzyme Replacement Therapy Market Growth & Trends:

The global enzyme replacement therapy market size is estimated to reach USD 17.26 billion by 2030, registering to grow at a CAGR of 9.0% from 2025 to 2030 according to a new report by Grand View Research, Inc. As per the Genetic and Rare Diseases Information Center or GARD, a rare disease is defined as a condition that affects lesser than 200,000 individuals. These disorders are also called orphan diseases due to the lack of support exhibited by pharmaceutical companies previously. Since the passing of the Orphan Drug Act of 1983 in the U.S., several large pharmaceutical and biopharmaceutical companies have invested heavily in the development of orphan drugs. Thus, rising awareness, increasing R&D investment, growth in the number of lysosomal storage and genetic disorders, and easy drug approval process are factors propelling the market growth during the forecast period.

According to data from the National Institutes of Health, it is estimated that over 25 million Americans suffer from rare diseases. These facts are indicative of the fact that although the number of these ailments is low, individuals suffering from these are large. Some of the most common lysosomal storage disorders that make use of enzyme replacement therapy are Gaucher, Fabry, Pompe, MPS, SCID, and Shwachman-Diamond Syndrome among others.

In the recent past, these disorders have been gaining significant attention, impacting growth positively. Various grants and acts are in place to accommodate drug makers to invest in the development of orphan drugs. Orphan Drug Designation Program, Rare Pediatric Disease Priority Review Voucher Program, Humanitarian Use Device (HUD) Program, and Orphan Products Clinical Trials Grants Program are programs that aid in the development of orphan drugs.

The rising use of enzyme replacement therapy in home care and infusion centers are gaining traction in the market. Specialized infusion centers such as these are anticipated to witness the highest CAGR during the forecast period. Hospitals held the largest segmental share owing to easy accessibility and ability to treat a wide range of ailments.

Enzyme Replacement Therapy Market Report Highlights:

• Gaucher disease held the dominant position in the market and accounted for the largest revenue share of 32.6% in 2024, driven by the increasing prevalence and awareness of the condition, leading to more patients being diagnosed and treated.
• Imiglucerase dominated the market and accounted for the largest revenue share of 20.2% in 2024, owing to the rising prevalence of Gaucher disease, which necessitates effective treatment options. In addition, as awareness and diagnosis rates improve, more patients are being identified, increasing demand for imiglucerase.
• The parenteral route of administration dominated the market and accounted for the largest revenue share of 80.9% in 2024. This growth is attributed to its ability to facilitate rapid absorption and effective drug delivery. In addition, this method allows for intravenous infusions, which are essential for delivering large molecules such as enzymes directly into the bloodstream, ensuring immediate therapeutic effects
• Infusion centers led the market and accounted for the largest revenue share of 40.8% in 2024, driven by their specialized focus on intravenous treatments. These centers provide a controlled environment for administering ERT, ensuring patient safety and comfort during infusions.

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
• 1.2. Segment Definitions
  • 1.2.1. Product
  • 1.2.2. Therapeutic Condition
  • 1.2.3. Route of Administration
  • 1.2.4. End Use
• 1.3. Estimates and Forecast Timeline
• 1.4. Research Methodology
• 1.5. Information Procurement
  • 1.5.1. Purchased Database
  • 1.5.2. GVR's Internal Database
  • 1.5.3. Secondary Sources
  • 1.5.4. Primary Research
• 1.6. Information Analysis
  • 1.6.1. Data Analysis Models
• 1.7. Market Formulation & Data Visualization
• 1.8. Model Details
  • 1.8.1. Commodity Flow Analysis
• 1.9. List of Secondary Sources
• 1.10. Objectives

Chapter 2. Executive Summary

• 2.1. Market Snapshot
• 2.2. Segment Snapshot
• 2.3. Competitive Landscape Snapshot

Chapter 3. Enzyme Replacement Therapy Market Variables, Trends, & Scope

• 3.1. Market Lineage Outlook
• 3.2. Market Dynamics
  • 3.2.1. Market Driver Analysis
  • 3.2.2. Market Restraint Analysis
• 3.3. Business Environment Analysis
  • 3.3.1. Industry Analysis - Porter's Five Forces Analysis
    • 3.3.1.1. Supplier power
    • 3.3.1.2. Buyer power
    • 3.3.1.3. Substitution threat
    • 3.3.1.4. Threat of new entrant
    • 3.3.1.5. Competitive rivalry
  • 3.3.2. PESTLE Analysis

Chapter 4. Enzyme Replacement Therapy Market: Product Business Analysis

• 4.1. Product Market Share, 2024 & 2030
• 4.2. Product Segment Dashboard
• 4.3. Market Size & Forecasts and Trend Analysis, by Product, 2018 to 2030 (USD Million)
• 4.4. Imiglucerase
  • 4.4.1. Imiglucerase Market, 2018 - 2030 (USD Million)
• 4.5. Agalsidase Beta
  • 4.5.1. Agalsidase Beta Market, 2018 - 2030 (USD Million)
  • 4.5.2. Alglucosidase Alfa
  • 4.5.3. Alglucosidase Alfa Market, 2018 - 2030 (USD Million)
• 4.6. Taliglucerase
  • 4.6.1. Taliglucerase Market, 2018 - 2030 (USD Million)
• 4.7. Velaglucerase Alfa
  • 4.7.1. Velaglucerase Alfa Market, 2018 - 2030 (USD Million)
• 4.8. Pegademase
  • 4.8.1. Pegademase Market, 2018 - 2030 (USD Million)
• 4.9. Laronidase
  • 4.9.1. Laronidase Market, 2018 - 2030 (USD Million)
• 4.10. Pancreatic Enzymes
  • 4.10.1. Pancreatic Enzymes Market, 2018 - 2030 (USD Million)
• 4.11. Idursulfase
  • 4.11.1. Idursulfase Market, 2018 - 2030 (USD Million)
• 4.12. Galsulfase
  • 4.12.1. Galsulfase Market, 2018 - 2030 (USD Million)
• 4.13. Others
  • 4.13.1. Others Market, 2018 - 2030 (USD Million)

Chapter 5. Enzyme Replacement Therapy Market: Therapeutic Condition Business Analysis

• 5.1. Therapeutic Condition Market Share, 2024 & 2030
• 5.2. Therapeutic Condition Segment Dashboard
• 5.3. Market Size & Forecasts and Trend Analysis, by Therapeutic Condition, 2018 to 2030 (USD Million)
• 5.4. Gaucher Disease
  • 5.4.1. Gaucher Disease Market, 2018 - 2030 (USD Million)
• 5.5. MPS
  • 5.5.1. MPS Market, 2018 - 2030 (USD Million)
• 5.6. SCID
  • 5.6.1. SCID Market, 2018 - 2030 (USD Million)
• 5.7. Pompe Disease
  • 5.7.1. Pompe Disease Market, 2018 - 2030 (USD Million)
• 5.8. Fabry Disease
  • 5.8.1. Fabry Disease Market, 2018 - 2030 (USD Million)
• 5.9. Other
  • 5.9.1. Other Market, 2018 - 2030 (USD Million)

Chapter 6. Enzyme Replacement Therapy Market: Route of Administration Business Analysis

• 6.1. Route of Administration Market Share, 2024 & 2030
• 6.2. Route of Administration Segment Dashboard
• 6.3. Market Size & Forecasts and Trend Analysis, by Route of Administration, 2018 to 2030 (USD Million)
• 6.4. Parenteral
  • 6.4.1. Parenteral Market, 2018 - 2030 (USD Million)
• 6.5. Oral
  • 6.5.1. Oral Market, 2018 - 2030 (USD Million)

Chapter 7. Enzyme Replacement Therapy Market: End Use Business Analysis

• 7.1. End Use Market Share, 2024 & 2030
• 7.2. End Use Segment Dashboard
• 7.3. Market Size & Forecasts and Trend Analysis, by End Use, 2018 to 2030 (USD Million)
• 7.4. Infusion Centers
  • 7.4.1. Infusion Centers Market, 2018 - 2030 (USD Million)
• 7.5. Hospitals
  • 7.5.1. Hospitals Market, 2018 - 2030 (USD Million)
• 7.6. Other
  • 7.6.1. Other Market, 2018 - 2030 (USD Million)

Chapter 8. Enzyme Replacement Therapy Market: Regional Estimates & Trend Analysis by Product, Therapeutic Condition, and End Use

• 8.1. Regional Market Share Analysis, 2024 & 2030
• 8.2. Regional Market Dashboard
• 8.3. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
• 8.4. North America
  • 8.4.1. North America Enzyme Replacement Therapy Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.4.2. U.S.
    • 8.4.2.1. Key Country Dynamic
    • 8.4.2.2. Regulatory Framework
    • 8.4.2.3. Competitive Insights
    • 8.4.2.4. U.S. Enzyme Replacement Therapy Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.4.3. Canada
    • 8.4.3.1. Key Country Dynamic
    • 8.4.3.2. Regulatory Framework
    • 8.4.3.3. Competitive Insights
    • 8.4.3.4. Canada Enzyme Replacement Therapy Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.4.4. Mexico
    • 8.4.4.1. Key Country Dynamic
    • 8.4.4.2. Regulatory Framework
    • 8.4.4.3. Competitive Insights
    • 8.4.4.4. Mexico Enzyme Replacement Therapy Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 8.5. Europe
  • 8.5.1. Europe Enzyme Replacement Therapy Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.5.2. UK
    • 8.5.2.1. Key Country Dynamic
    • 8.5.2.2. Regulatory Framework
    • 8.5.2.3. Competitive Insights
    • 8.5.2.4. UK Enzyme Replacement Therapy Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.5.3. Germany
    • 8.5.3.1. Key Country Dynamic
    • 8.5.3.2. Regulatory Framework
    • 8.5.3.3. Competitive Insights
    • 8.5.3.4. Germany Enzyme Replacement Therapy Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.5.4. France
    • 8.5.4.1. Key Country Dynamic
    • 8.5.4.2. Regulatory Framework
    • 8.5.4.3. Competitive Insights
    • 8.5.4.4. France Enzyme Replacement Therapy Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.5.5. Italy
    • 8.5.5.1. Key Country Dynamic
    • 8.5.5.2. Regulatory Framework
    • 8.5.5.3. Competitive Insights
    • 8.5.5.4. Italy Enzyme Replacement Therapy Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.5.6. Spain
    • 8.5.6.1. Key Country Dynamic
    • 8.5.6.2. Regulatory Framework
    • 8.5.6.3. Competitive Insights
    • 8.5.6.4. Spain Enzyme Replacement Therapy Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.5.7. Norway
    • 8.5.7.1. Key Country Dynamic
    • 8.5.7.2. Regulatory Framework
    • 8.5.7.3. Competitive Insights
    • 8.5.7.4. Norway Enzyme Replacement Therapy Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.5.8. Denmark
    • 8.5.8.1. Key Country Dynamic
    • 8.5.8.2. Regulatory Framework
    • 8.5.8.3. Competitive Insights
    • 8.5.8.4. Denmark Enzyme Replacement Therapy Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.5.9. Sweden
    • 8.5.9.1. Key Country Dynamic
    • 8.5.9.2. Regulatory Framework
    • 8.5.9.3. Competitive Insights
    • 8.5.9.4. Sweden Enzyme Replacement Therapy Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 8.6. Asia Pacific
  • 8.6.1. Asia Pacific Enzyme Replacement Therapy Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.6.2. Japan
    • 8.6.2.1. Key Country Dynamic
    • 8.6.2.2. Regulatory Framework
    • 8.6.2.3. Competitive Insights
    • 8.6.2.4. Japan Enzyme Replacement Therapy Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.6.3. China
    • 8.6.3.1. Key Country Dynamic
    • 8.6.3.2. Regulatory Framework
    • 8.6.3.3. Competitive Insights
    • 8.6.3.4. China Enzyme Replacement Therapy Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.6.4. India
    • 8.6.4.1. Key Country Dynamic
    • 8.6.4.2. Regulatory Framework
    • 8.6.4.3. Competitive Insights
    • 8.6.4.4. India Enzyme Replacement Therapy Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.6.5. South Korea
    • 8.6.5.1. Key Country Dynamic
    • 8.6.5.2. Regulatory Framework
    • 8.6.5.3. Competitive Insights
    • 8.6.5.4. South Korea Enzyme Replacement Therapy Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.6.6. Australia
    • 8.6.6.1. Key Country Dynamic
    • 8.6.6.2. Regulatory Framework
    • 8.6.6.3. Competitive Insights
    • 8.6.6.4. Australia Enzyme Replacement Therapy Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.6.7. Thailand
    • 8.6.7.1. Key Country Dynamic
    • 8.6.7.2. Regulatory Framework
    • 8.6.7.3. Competitive Insights
    • 8.6.7.4. Thailand Enzyme Replacement Therapy Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 8.7. Latin America
  • 8.7.1. Latin America Enzyme Replacement Therapy Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.7.2. Brazil
    • 8.7.2.1. Key Country Dynamic
    • 8.7.2.2. Regulatory Framework
    • 8.7.2.3. Competitive Insights
    • 8.7.2.4. Brazil Enzyme Replacement Therapy Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.7.3. Argentina
    • 8.7.3.1. Key Country Dynamic
    • 8.7.3.2. Regulatory Framework
    • 8.7.3.3. Competitive Insights
    • 8.7.3.4. Argentina Enzyme Replacement Therapy Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 8.8. MEA
  • 8.8.1. MEA Enzyme Replacement Therapy Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.8.2. South Africa
    • 8.8.2.1. Key Country Dynamic
    • 8.8.2.2. Regulatory Framework
    • 8.8.2.3. Competitive Insights
    • 8.8.2.4. South Africa Enzyme Replacement Therapy Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.8.3. Saudi Arabia
    • 8.8.3.1. Key Country Dynamic
    • 8.8.3.2. Regulatory Framework
    • 8.8.3.3. Competitive Insights
    • 8.8.3.4. Saudi Arabia Enzyme Replacement Therapy Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.8.4. UAE
    • 8.8.4.1. Key Country Dynamic
    • 8.8.4.2. Regulatory Framework
    • 8.8.4.3. Competitive Insights
    • 8.8.4.4. UAE Enzyme Replacement Therapy Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.8.5. Kuwait
    • 8.8.5.1. Key Country Dynamic
    • 8.8.5.2. Regulatory Framework
    • 8.8.5.3. Competitive Insights
    • 8.8.5.4. Kuwait Enzyme Replacement Therapy Market Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 9. Competitive Landscape

• 9.1. Participant Overview
• 9.2. Company Market Position Analysis
• 9.3. Company Categorization
• 9.4. Strategy Mapping
• 9.5. Company Profiles/Listing
  • 9.5.1. Carl Zeiss Meditec, Inc.
    • 9.5.1.1. Overview
    • 9.5.1.2. Financial Performance
    • 9.5.1.3. Product Benchmarking
    • 9.5.1.4. Strategic Initiatives
  • 9.5.2. Shire Plc;
    • 9.5.2.1. Overview
    • 9.5.2.2. Financial Performance
    • 9.5.2.3. Product Benchmarking
    • 9.5.2.4. Strategic Initiatives
  • 9.5.3 Sanofi S.A.
    • 9.5.2.1. Overview
    • 9.5.2.2. Financial Performance
    • 9.5.2.3. Product Benchmarking
    • 9.5.2.4. Strategic Initiatives
  • 9.5.4. Biomarin Pharmaceutical Inc.
    • 9.5.4.1. Overview
    • 9.5.4.2. Financial Performance
    • 9.5.4.3. Product Benchmarking
    • 9.5.4.4. Strategic Initiatives
  • 9.5.5. AbbVie
    • 9.5.5.1. Overview
    • 9.5.5.2. Financial Performance
    • 9.5.5.3. Product Benchmarking
    • 9.5.5.4. Strategic Initiatives
  • 9.5.6. Alexion Pharmaceuticals Inc.
    • 9.5.6.1. Overview
    • 9.5.6.2. Financial Performance
    • 9.5.6.3. Product Benchmarking
    • 9.5.6.4. Strategic Initiatives
  • 9.5.7. Allergan plc
    • 9.5.7.1. Overview
    • 9.5.7.2. Financial Performance
    • 9.5.7.3. Product Benchmarking
    • 9.5.7.4. Strategic Initiatives
  • 9.5.8. Horizon Pharma Public Limited Company
    • 9.5.8.1. Overview
    • 9.5.8.2. Financial Performance
    • 9.5.8.3. Product Benchmarking
    • 9.5.8.4. Strategic Initiatives
  • 9.5.9. Actelion (Janssen)
    • 9.5.9.1. Overview
    • 9.5.9.2. Financial Performance
    • 9.5.9.3. Product Benchmarking
    • 9.5.9.4. Strategic Initiatives
  • 9.5.10. Recordati Rare Diseases
    • 9.5.10.1. Overview
    • 9.5.10.2. Financial Performance
    • 9.5.10.3. Product Benchmarking
    • 9.5.10.4. Strategic Initiatives
  • 9.5.11. Protalix Biotherapeutics
    • 9.5.11.1. Overview
    • 9.5.11.2. Financial Performance
    • 9.5.11.3. Product Benchmarking
    • 9.5.11.4. Strategic Initiatives
  • 9.5.12. Amicus Therapeutics, Inc.
    • 9.5.12.1. Overview
    • 9.5.12.2. Financial Performance
    • 9.5.12.3. Product Benchmarking
    • 9.5.12.4. Strategic Initiatives

관련자료